The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells.
about
Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodiesUBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemiaCloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genesRare Cytogenetic Abnormalities and Alteration of microRNAs in Acute Myeloid Leukemia and Response to TherapyThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesPerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsProgress in acute myeloid leukemiaRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsRetinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemiaPML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse modelAll-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaAutophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein.Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cellsAddition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic LeukemiaTreatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins.Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cellsInduction treatments for acute promyelocytic leukemia: a network meta-analysis.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.The nuclear bodies inside out: PML conquers the cytoplasm.Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.Retinoic acid, CYP26, and drug resistance in the stem cell niche.NLS-RARα is a novel transcriptional factor.Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.Regulation of cell surface protease receptor S100A10 by retinoic acid therapy in acute promyelocytic leukemia (APL)
P2860
Q24311314-402229C4-77A0-4075-B631-1C702128FE76Q24533339-7EF1D14D-72AE-4C68-9C3B-29C25027480FQ24655577-4EF64225-4078-46BA-8D7D-A7F854D7554AQ26771425-6C0622B3-89BE-430E-9612-169CDF1D3E39Q26853348-C35EE733-AA5A-4BA9-8527-B2722080A954Q26991440-9C81927D-131B-46A5-9145-75725F51E4FFQ27024006-4E5D80CA-5BB2-4C2D-96A7-00375DFFA595Q28344657-AA15A9DD-9BAE-4870-A696-BEE581580C2FQ33178068-EAAF3196-CF5C-4A80-B0E9-C0DB62D590F5Q34032333-A6B1AFE8-45C8-487A-8256-C6EE5C8894AAQ34546653-FAFFB5D7-912D-44A0-B0DC-C7C0885D87D6Q35079502-FB58F137-EA63-46FD-83F3-99F61FF976B9Q35677279-956814DF-5E1B-4016-B313-3BE29959E4B8Q35904994-CC7AD3AD-4BEA-4496-84D3-F6007FE1F57FQ36732473-0EC2641B-3976-490B-8656-360ED1348D0BQ36774571-12A5F640-4709-4601-9BBE-BE52E420C058Q37117735-A27EC59B-266C-4EBC-9BC6-C33C696BB643Q37151474-4B42A34D-DECB-4A47-B265-8199A035858EQ37397791-E415CAC7-1927-44F9-B3E5-B4382DEB9567Q37420045-FD24EB23-8FCD-4DA4-9B59-3AC76DB0FD06Q37687750-C4C13D78-9976-4E3B-B11F-EA113BD881BAQ37712353-788AEA19-239E-40E6-B299-0423C7832876Q37866490-93D85AE0-310D-4D73-9479-8201001C65D8Q37973346-5BF0A891-B5C4-4107-A2B5-4689306A8903Q40454835-F438C120-F88D-4F31-A51D-5F432F10210BQ48015915-11F15244-C058-421B-85E7-D471D7127B37Q49986992-09AC41F2-85FC-4F23-8BFD-1070E95111DEQ55399708-1968F79B-F2E2-4553-B041-03AA678A8662Q58751591-51065008-DC16-4B3D-9761-5E6BD8F88920
P2860
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells.
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@ast
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@en
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@nl
type
label
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@ast
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@en
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@nl
prefLabel
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@ast
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@en
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@nl
P2093
P1433
P1476
The PML/RAR alpha oncoprotein ...... promyelocytic leukemia cells.
@en
P2093
Benedetti L
Miller WH Jr
Pelicci PG
Raelson JV
Rosenauer A
P304
P407
P577
1996-10-01T00:00:00Z